Liao F.,Nanjing PLA 81 Hospital |
Wang L.,Nanjing PLA 81 Hospital |
Qin S.-K.,Nanjing PLA 81 Hospital |
Li X.-W.,Nanjing PLA 81 Hospital |
And 4 more authors.
Journal of Practical Oncology | Year: 2014
Objective: To investigate fluorouracil-induced cardiac toxicity in cancer patients. Methods: The cardiac toxicity of 9 patients with advanced colorectal cancer receiving FOLFOX6 scheme containing fluorouracil was retrospectively analyzed and the relevant literatures were reviewed. Cardiac toxicity was graded according to the CTCAE version 4. Results: Arrhythmia was the most common cardiac toxicity, occurring in 77.8% patients (7/9), followed by angina pectoris (22.2%, 2/9) and asymptomatic myocardial ischemia (22.2%, 2/9). Most patients had grade 1~2 cardiac toxicity. Raltitrexed was replaced in 3 patients, among whom arrhythmia was relieved in 2 cases, and reduced from grade 2 to grade 1 in one case. Among 4 cases discontinuing 5-FU, cardiac toxicity was relieved in 3 and not aggravated in one. In the other 2 cases chemotherapy was suspended or delayed and cardiac toxicity was relieved. Conclusion: 5-FU is most commonly used as chemotherapeutic agent with broad-spectrum and effectiveness, but heart toxicity induced by 5-FU cannot be ignored.